{"id":2785,"date":"2025-02-03T15:39:17","date_gmt":"2025-02-03T12:39:17","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2785"},"modified":"2025-03-07T13:17:20","modified_gmt":"2025-03-07T10:17:20","slug":"entrada-therapeutics-receives-uk-authorization-to-begin-elevate-44-201","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/entrada-therapeutics-receives-uk-authorization-to-begin-elevate-44-201\/","title":{"rendered":"Entrada Therapeutics re\u00e7oit l&#039;autorisation du Royaume-Uni pour lancer ELEVATE-44-201"},"content":{"rendered":"<p class=\"wp-block-paragraph\">ELEVATE-44-201, une \u00e9tude clinique de phase 1\/2 \u00e0 doses multiples croissantes (MAD) d&#039;ENTR-601-44, a \u00e9t\u00e9 autoris\u00e9e par l&#039;Agence de r\u00e9glementation des m\u00e9dicaments et des produits de sant\u00e9 (MHRA) du Royaume-Uni et par le Comit\u00e9 d&#039;\u00e9thique de la recherche pour l&#039;essai clinique d&#039;un m\u00e9dicament exp\u00e9rimental. L&#039;\u00e9tude vise \u00e0 traiter la dystrophie musculaire de Duchenne (DMD) chez les patients pr\u00e9sentant une mutation confirm\u00e9e du g\u00e8ne DMD susceptible de sauter l&#039;exon 44.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Qu\u2019est-ce que l\u2019\u00e9tude clinique ELEVATE-44-201\u00a0?<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">ELEVATE-44-201 est une \u00e9tude mondiale de phase 1\/2, en deux parties, randomis\u00e9e, en double aveugle, contr\u00f4l\u00e9e par placebo, \u00e9valuant l&#039;innocuit\u00e9, la tol\u00e9rance et l&#039;efficacit\u00e9 d&#039;ENTR-601-44 chez les patients ambulatoires atteints de DMD et susceptibles de sauter l&#039;exon 44.<\/p>","protected":false},"excerpt":{"rendered":"<p>ELEVATE-44-201, a Phase 1\/2 multiple ascending dose (MAD) clinical study of ENTR-601-44, was authorized by the UK&#8217;s Medicines and Healthcare Products Regulatory Agency (MHRA) and Research Ethics Committee for the Clinical Trial of an Investigational Medicinal Product. The study aims to treat Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2788,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[235,49,233,234,141,127,77,48],"class_list":["post-2785","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-elevate-44-201","tag-england","tag-entrada","tag-entrada-therapeutics","tag-exon-44","tag-exon-44-skipping","tag-exon-skipping","tag-uk"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/2785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=2785"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/2785\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/2788"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=2785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=2785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=2785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}